Gastroenterology

Adherence to an adapted low FODMAP diet and its impact on IBS symptoms were not affected based on the presence of fibromyalgia.

Linaclotide was safe and effective for patients with chronic constipation and IBS with constipation who switched after non-response to magnesium oxide.

In focus groups, patients indicated symptom bothersomeness and life interference should be included in clinical evaluation for disorders of gut-brain interaction.

Patients taking GLP-1 RAs were more likely to show food retention and inadequate bowel preparation, even when the medications were held before the procedure.

The approval is based on findings from BLUE-C, where Cologuard Plus demonstrated sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity.

This month in review spotlights recent GI pipeline news, new research about IBS and other gastroenterological conditions, and coverage from the 2024 GHAPP conference.

Compared to those without SLD, patients with MASLD, MetALD, and other combination etiology had a greater risk of developing liver and gastrointestinal cancers.

Crimaldi reviews key considerations for the diagnosis and management of bowel ischemia, diverticulitis, and small bowel obstructions in GI inpatients.

Subgroup analyses revealed FMT delivered through endoscopy, nasojejunal tube, and rectal enema had a greater impact on clinical response, symptom improvement, and quality of life.

Oral vitamin D improves vitamin D status and quality of life in IBS patients but does not significantly reduce symptom severity, a new study suggests.

A new study finds causal links between schizophrenia and MDD on IBS, highlighting the need for integrated care addressing both psychiatric and gastrointestinal symptoms.

The FDA declined to approve the NDA for tradipitant for the treatment of symptoms of gastroparesis, suggesting that Vanda conduct additional studies.

Banty discusses recent advancements in the ulcerative colitis and Crohn disease treatment landscapes, explaining how to navigate the growing number of treatment options.

Richards describes the utility of different NITs in primary and specialty care for risk-stratifying patients with MASH and fibrosis.

Solomon explains how to navigate the growing Crohn disease treatment armamentarium and the importance of treatment positioning.

Martinez de Andino reviews key considerations for the management of DGBI with brain-gut behavioral therapy and neuromodulators.

The decision is based on rates of clinical and endoscopic remission with guselkumab in the ongoing phase 2b/3 QUASAR study.

Findings highlight disease burden and ongoing unmet needs in patients with IBS-C and IBS-D, suggesting the benefit of prescription medications on rates of satisfaction and symptom control.

Patients with positive endoscopic findings for upper gastrointestinal mucosal damage had a greater risk of developing Parkinson disease compared to those without mucosal damage.

A new study discovers patients with IBD who respond well to high-dose thiamine treatment have an abundance of faecalibacterium prausnitzii.

The HCPLive August gastroenterology month in review spotlights expansions in gastrointestinal treatment and screening access as well as the newest edition of Qazi Corner.

AHN Division of Gastroenterology, Hepatology, and Nutrition addresses patients’ challenging symptoms and needs with wide-ranging strategies and innovative treatments.

Qazi discusses a review of considerations for GLP-1 RA use in the context of endoscopic procedures due to their impact on gastric emptying and bowel motility.

With the growing popularity of GLP-1 receptor agonists, understanding their impact on gastric emptying, bowel motility, and potential implications for endoscopy is essential.